Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

scientific article published in the British Medical Journal

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1136/BMJ.K4365
P932PMC publication ID6233755
P698PubMed publication ID30429124

P50authorMads MelbyeQ28759321
Soffia GudbjörnsdottirQ60608171
Peter UedaQ63819496
Ann-Marie SvenssonQ98840964
Kristian HveemQ32984975
Björn PasternakQ50561779
P2093author name stringBjörn Eliasson
Henrik Svanström
Christian Jonasson
Stefan Franzén
P2860cites workThe Danish National Patient Registry: a review of content, data quality, and research potentialQ26775834
Acute kidney injury from SGLT2 inhibitors: potential mechanisms.Q53796258
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSISQ63071443
Canagliflozin-Associated Acute PancreatitisQ85248009
Amputations and foot ulcers in patients newly diagnosed with type 2 diabetes mellitus and observed for 19 years. The role of age, gender and co-morbidityQ86654822
Diabetes: SGLT2 inhibitors and diabetic ketoacidosis - a growing concernQ88326701
SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting SystemQ88579083
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effectsQ95561229
Performance and limitations of administrative data in the identification of AKI.Q30741347
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.Q33890770
External review and validation of the Swedish national inpatient registerQ33928068
Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trialsQ34664185
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesQ34673134
Canagliflozin-induced pancreatitis: a rare side effect of a new drug.Q35811434
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.Q35968414
Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesQ36050559
Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With CanagliflozinQ36431654
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes MellitusQ36431670
The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary applicationQ36653410
Multiple imputation: review of theory, implementation and softwareQ36719605
Possible adverse effects of SGLT2 inhibitors on boneQ36988902
Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation studyQ37454809
Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuriaQ38188185
Ketoacidosis and SGLT2 inhibitor treatment: Analysis of FAERS data.Q38665387
Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesQ38729780
Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 DiabetesQ38962076
Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulationsQ45183983
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 DiabetesQ46113283
Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system databaseQ47366627
Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential AnalysisQ47652080
One-to-many propensity score matching in cohort studies.Q47789199
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trialsQ47918474
Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME TrialQ48313349
Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort studyQ48360915
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?Q48374438
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018.Q49988613
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real WQ50042476
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.Q50955035
Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents.Q51032023
Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.Q51737719
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.Q53084508
P407language of work or nameEnglishQ1860
P304page(s)k4365
P577publication date2018-11-14
P1433published inThe BMJQ546003
P1476titleSodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
P478volume363

Reverse relations

cites work (P2860)
Q92535991Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
Q64355352Canagliflozin should be prescribed with caution to individuals with type 2 diabetes and high risk of amputation
Q92028398Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
Q92544099Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study
Q92131836Class effect for SGLT-2 inhibitors: a tale of 9 drugs
Q90259243Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
Q64245217Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
Q64904716Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy.
Q95282509Euglycemic Diabetic Ketoacidosis in Concurrent Very Low-carbohydrate Diet and Sodium-glucose Transporter-2 Inhibitor Use: A Case Report
Q91937581Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes
Q90465947Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes
Q92835456Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes
Q92462642Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
Q90676214SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
Q92703271SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Q92853232SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
Q98778627Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Q89963471Therapeutic Inertia in Pediatric Diabetes: Challenges to and Strategies for Overcoming Acceptance of the Status Quo
Q92992644Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study
Q94554818Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study

Search more.